BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2018 pay slips 2% to $16M
BioMarin Pharmaceutical reports 2018 executive compensation
By ExecPay News
Published: April 23, 2019
BioMarin Pharmaceutical reported fiscal year 2018 executive compensation information on April 23, 2019.
In 2018, six executives at BioMarin Pharmaceutical received on average a compensation package of $6.1M, a 17% decrease compared to previous year.
Average pay of disclosed executives at BioMarin Pharmaceutical
Jean-Jacques Bienaim, Chief Executive Officer, received $16M in total, which decreased by 2% compared to 2017. 50% of Bienaim's compensation, or $7.7M, was in stock awards. Bienaim also received $1.7M in non-equity incentive plan, $5M in option awards, $1.1M in salary, as well as $65K in other compensation.
For fiscal year 2018, the median employee pay was $160,698 at BioMarin Pharmaceutical. Therefore, the ratio of Jean-Jacques Bienaim's pay to the median employee pay was 97 to one.
Henry J. Fuchs, President, Worldwide R&D, received a compensation package of $5.8M, which decreased by 18% compared to previous year. 46% of the compensation package, or $2.7M, was in stock awards.
Jeff Ajer, Executive Vice President, Chief Commercial Officer, earned $4.5M in 2018, a 1% decrease compared to previous year.
Daniel Spiegelman, Chief Financial Officer, received $4.5M in 2018, which decreases by 3% compared to 2017.
Robert A. Baffi, Executive Vice President, Technical Operations, earned $4.4M in 2018, a 1% decrease compared to previous year.
Brian R. Mueller, Chief Financial Officer, received $1.5M in 2018.
Related executives
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
Daniel Spiegelman
BioMarin Pharmaceutical
Chief Financial Officer
Jeff Ajer
BioMarin Pharmaceutical
Executive Vice President, Chief Commercial Officer
Robert Baffi
BioMarin Pharmaceutical
Former President of Global Manufacturing and Technical Operations
Henry Fuchs
BioMarin Pharmaceutical
President, Worldwide R&D
Brian Mueller
BioMarin Pharmaceutical
Chief Financial Officer
You may also like
Source: SEC filing on April 23, 2019.